NewAmsterdam Pharma (NAMS) drew fresh attention after reporting first quarter 2026 results that came in ahead of revenue and earnings estimates, while management highlighted several upcoming clinical and regulatory milestones.

The stock reacted sharply to the update, with a 1 day share price return of 12.46% and a 7 day share price return of 22.02%. This comes even though the year to date share price return is slightly negative, while the 1 year total shareholder return of 80.85% points to strong longer term momentum.

If you are looking beyond one biopharma story and want to see what else is moving on clinical and regulatory news, consider scanning a broader set of healthcare focused AI opportunities through 35 healthcare AI stocks

With NewAmsterdam Pharma still loss making, yet trading at a steep discount to published analyst targets and some internal value estimates, you have to ask: is there mispricing here, or is the market already banking on future growth?

Preferred Price to Book of 5.9x: Is It Justified?

On the latest data, NewAmsterdam Pharma trades at a P/B of 5.9x, which screens as expensive relative to both the US Biotechs industry and its closest peers.

P/B compares the share price to the company’s book value per share. A higher ratio often reflects investor willingness to pay more for assets that are expected to generate stronger future cash flows.

For NewAmsterdam Pharma, this 5.9x P/B sits well above the US Biotechs industry average of 2.5x, and is slightly above the peer average of 5.7x. This suggests the market is assigning a premium that is higher than the broader sector and even a touch rich versus more closely comparable companies.

Result: Price-to-book of 5.9x (OVERVALUED)

However, the story can change quickly if key Obicetrapib trials disappoint or if ongoing losses of US$203.819 million limit funding flexibility for longer development timelines.

Another Angle: DCF Points in the Opposite Direction

The earlier P/B check paints NAMS as expensive, but our DCF model suggests a different perspective. With the stock at $34.85 and the model indicating a future cash flow value of $137.55, NAMS is described as trading 74.7% below fair value. This raises the question of which signal might be more informative.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out NewAmsterdam Pharma for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

The mix of signals here may feel conflicting. If you care about acting before sentiment shifts, run the numbers yourself and weigh both sides of the story with 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop here, you only see one part of the opportunity set. Cast the net wider, compare different types of stocks, and give yourself more options.

• Spot potential bargains early and see which companies stand out on valuation and quality using the 51 high quality undervalued stocks.
• Prioritise strength by focusing on companies with healthier finances through the solid balance sheet and fundamentals stocks screener (44 results).
• Unearth lesser known opportunities that still clear solid fundamental checks with the screener containing 23 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.